Skip to Main Content

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Last night, we held our 2024 STATUS List dinner, honoring 50 influential people shaping the future of health, medicine and life sciences. It was an amazing evening, and a chance to eat and chat with some brilliant and engaging honorees. At dinner, to my left, was Biogen CEO Chris Viehbacher; to my right, Avoro Capital’s Behzad Aghazadeh. I sat directly across from Novo Nordisk scientist Lotte Knudsen. AstraZeneca’s cancer R&D chief Susan Galbraith and Harvard’s sickle cell scientist Stuart Orkin were nearby. Incredible. The chicken was delicious.

advertisement

This week, I crunched some performance numbers for biotech PIPES, and chatted with the CEO of Benitec Biopharma about its gene therapy for a rare genetic disorder that weakens muscles around the throat. Plus, biotech watercooler updates on Vera Therapeutics and Biohaven Pharma. As always, send feedback and questions to [email protected]

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.